A Decision Resources, Inc. study reveals physician and HMO plans for cholesterol management as a result of the introduction of novel therapies, release of new guidelines that redefine at- risk groups, and shifts in formulary placement of existing and novel statins. Decision Resources, in partnership with MedPanel, Inc., announces the publication of Physician Forum-Treating Hyperlipidemia in the United States: A Discussion of Evolving Medical Practice, a primary-research-based study that offers a vital enhancement to the strategic decision making process of companies vying for a competitive position in the face of new market developments.
Key elements of these threaded discussions with U.S. primary care physicians, hyperlipidemia experts (cardiologists with clinical and research expertise), and large, independent HMO pharmacy directors include the following:
* LDL:HDL ratios -- Assessing the level of unmet need in raising HDL levels. * Physician opinions on adherence to new guidelines. * HMO's concerns that increased treatment rates will bring higher costs. * The impact of the withdrawal of cerivastatin (Bayer's Lipobay/GlaxoSmithKline's Baycol) on physician prescribing habits and the formulary placement of statins. * The impact of upcoming generic statins on prescribing patterns and the formulary inclusion of statins.
The clinical data on the efficacy of rosuvastatin (AstraZeneca's Crestor) bode well for the future of this superstatin, according to the discussions between physicians and HMO pharmacy directors documented in this report. The panelists' discussions identify the type of clinical end-point data that would make them alter their current positions with respect to statins. The discussions also illuminate potential risks for atorvastatin (Pfizer's Lipitor) upon Crestor's launch.
The questions posed to panelists include the following: * What do you believe your formulary position will be for AstraZeneca's Crestor? * What data or experience do you need to change your current prescribing pattern? * In cases of several drugs in a class, i.e. statins, how do you tier them? * What are your first, second, and third line treatments for elevated cholesterol? Why? How does the choice change for different patient presentations? * Will combination therapy become more popular? Why? * Will the December 15, 2001 availability of generic lovastatin (Merck & Co.'s Mevacor) change prescribing patterns or formulary placement? * What is your opinion of this market in the next five years?
Physician Forum-Treating Hyperlipidemia in the United States: A Discussion of Evolving Medical Practice is available for $8,000.00
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Tim Daley, 781.296.2636 (telephone), 781.296.2525 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
MAKE YOUR OPINION COUNT - Click Here
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Alice Von Loesecke of Decision Resources, 781-296-2535, or